Targeting MDSC differentiation using ATRA: a phase I/II clinical trial combining pembrolizumab and all-trans retinoic acid for metastatic melanoma.

Richard P Tobin Dasha T Cogswell Victoria M Cates Dana M Davis Jessica S W Borgers Robert J Van Gulick Elizabeth Katsnelson Kasey L Couts Kimberley R Jordan Dexiang Gao Eduardo Davila Theresa M Medina Karl D Lewis Rene Gonzalez Ross W McFarland William A Robinson Martin D McCarter

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)

With a favorable tolerability and high response rate, this combination is a promising frontline treatment strategy for advanced melanoma. Targeting MDSCs remains an attractive mechanism to enhance the efficacy of immunotherapies and this combination merits further investigation.

Keyphrases

clinical trial
open label
cancer therapy

double blind
phase ii
study protocol

advanced non small cell lung cancer
randomized controlled trial
phase iii

placebo controlled
tyrosine kinase
basal cell carcinoma